Viewing Study NCT02616393


Ignite Creation Date: 2025-12-25 @ 1:06 AM
Ignite Modification Date: 2026-02-22 @ 7:02 AM
Study NCT ID: NCT02616393
Status: COMPLETED
Last Update Posted: 2022-03-16
First Post: 2015-11-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Sponsor: Kadmon Corporation, LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
None Leptomeningeal Metastases View
None Brain Metastases View
Keywords: